Vir Biotechnology, Gilead strike deal for novel tumor treatments
Vir Biotechnology Inc. VIR announced a major collaboration with Gilead Sciences Inc. GILD to create three novel T-cell ...
Model output · Signal date 2026-10-16
Vir Biotechnology, Inc. (VIR) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
▲ Bullish
Exact rating locked
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
Top 35%
of 5172 stocks scored
Rank correlation · 90D
36.0%
Spearman, 357 dates
Market Cap
$1.69B
small-cap · #38 of 60 peers
Summary
Vir Biotechnology, Inc. (VIR) stock forecast summary
Our AI ranks Vir Biotechnology, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Vir Biotechnology, Inc. is a small-cap company with a market capitalization of $1.69B. It ranks number 38 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast.
For VIR, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 36.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 19.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, VIR included.
Follow VIR freePrice
VIR price chart and AI forecast
Cross-section · 2026-10-16
How VIR ranks among 5172 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-06-30
Vir Biotechnology, Inc. (VIR) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.
Valuation & Market
| Metric | VIR | Rank |
|---|---|---|
| Market Cap | $1.69B | 38/60 |
| P/B Ratio | 1.72x | 45/49 |
| EPS | $-1.89 | – |
| Book Value/Share | $5.81 | – |
| FCF/Share | $-1.20 | – |
Profitability & Margins
| Metric | VIR | Rank |
|---|---|---|
| ROE | -25.6% | 19/47 |
| ROA | -20.7% | 24/50 |
| ROIC | -25.0% | 22/53 |
| Gross Margin | 83.7% | 6/24 |
| Operating Margin | -76.3% | 22/40 |
| Net Margin | -68.5% | 22/37 |
| EBT Margin | -68.4% | 24/42 |
| Tax Rate | -0.1% | – |
Financial Health
| Metric | VIR | Rank |
|---|---|---|
| Current Ratio | 6.04x | 27/59 |
| D/E Ratio | 0.24x | 34/53 |
| Financial Leverage | 1.24x | 33/52 |
| Working Capital | $479M | 27/59 |
Cash Flow
| Metric | VIR | Rank |
|---|---|---|
| Operating Cash Flow | -$203M | 41/57 |
| Free Cash Flow | -$204M | 36/50 |
| Capital Spending | -$1M | 11/50 |
Operational Efficiency
| Metric | VIR | Rank |
|---|---|---|
| Payables Period | 249239 days | 1/26 |
Income Statement
| Metric | VIR | Rank |
|---|---|---|
| Operating Income | -$280M | 38/54 |
| Net Income | -$252M | 35/50 |
| R&D Expense | $484M | 13/56 |
| SG&A Expense | $99M | 19/22 |
| Cost of Goods Sold | $30K | 26/26 |
Dividend & Shareholder Information
| Metric | VIR | Rank |
|---|---|---|
| Shares Outstanding | 169M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $574M | 47.2% of assets |
| Cash & Short-term Investments | $279M | 22.9% of assets |
| Total Liabilities | $232M | 19.1% of assets |
| Short-term Debt | $77M | 6.4% of assets |
Quarterly Financial Reports
VIR quarterly financials and insider trading
Industry Peers · Biological Products, (No Diagnostic Substances)
Vir Biotechnology, Inc. (VIR) industry peers
Companies classified under the same SEC industry code as Vir Biotechnology, Inc. (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| VIR Vir Biotechnology, Inc. | ▲ | $1.69B |
| AMGN Amgen Inc | ▼ | $233.82B |
| GILD Gilead Sciences, Inc. | ▲ | $193.67B |
| MRNA Moderna, Inc. | ▲ | $87.04B |
| ARGX Argenx Se | ▼ | $50.69B |
| RVMD Revolution Medicines, Inc. | ▲ | $38.14B |
| BIIB Biogen Inc. | ▼ | $34.13B |
| BNTX Biontech Se | ▲ | $22.18B |
| EXEL Exelixis, Inc. | ▶ | $15.42B |
| HALO Halozyme Therapeutics, Inc. | ▶ | $13.83B |
| NBIX Neurocrine Biosciences Inc | ▲ | $13.79B |
| TECH Bio-Techne Corp | ▼ | $11.38B |
| QGEN Qiagen N.V. | ▶ | $10.01B |
| RGEN Repligen Corp | ▲ | $9.90B |
| IBRX Immunitybio, Inc. | ▲ | $9.73B |
| PCVX Vaxcyte, Inc. | ▲ | $9.47B |
| KRYS Krystal Biotech, Inc. | ▶ | $9.37B |
| KYMR Kymera Therapeutics, Inc. | ▲ | $8.71B |
| TWST Twist Bioscience Corp | ▲ | $8.32B |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.17B |
| IMVT Immunovant, Inc. | ▲ | $5.52B |
| KOD Kodiak Sciences Inc. | ▲ | $5.39B |
| CGON Cg Oncology, Inc. | ▲ | $5.31B |
| SRRK Scholar Rock Holding Corp | ▲ | $4.86B |
| CRSP Crispr Therapeutics Ag | ▲ | $4.76B |
| ADPT Adaptive Biotechnologies Corp | ▲ | $3.83B |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.57B |
| TARS Tarsus Pharmaceuticals, Inc. | ▲ | $2.99B |
| DNLI Denali Therapeutics Inc. | ▼ | $2.81B |
| BEAM Beam Therapeutics Inc. | ▲ | $2.42B |
| ADMA Adma Biologics, Inc. | ▼ | $2.39B |
| LIFE Atyr Pharma Inc | ▲ | $2.37B |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.07B |
| VCEL Vericel Corp | ▶ | $2.05B |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $1.99B |
| NVAX Novavax Inc | ▲ | $1.86B |
| ALVO Alvotech | ▲ | $1.78B |
| MESO Mesoblast Ltd | ▶ | $1.70B |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.53B |
| IMCR Immunocore Holdings Plc | ▶ | $1.51B |
| COAG Hemab Therapeutics Holdings, Inc. | ▶ | $1.40B |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.18B |
| VOR Vor Biopharma Inc. | ▲ | $1.07B |
| REPL Replimune Group, Inc. | ▲ | $1.02B |
| JATT Zura Bio Ltd | ▶ | $994M |
| IMTX Immatics N.V. | ▲ | $902M |
| MGTX Meiragtx Holdings Plc | ▶ | $891M |
| SLBT Sl Science Holding Ltd | ▶ | $884M |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $832M |
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $831M |
| ODTX Odyssey Therapeutics, Inc. | ▲ | $825M |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $692M |
| SANA Sana Biotechnology, Inc. | ▲ | $680M |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $670M |
| AURA Aura Biosciences, Inc. | ▲ | $633M |
| PRME Prime Medicine, Inc. | ▲ | $629M |
| CADL Candel Therapeutics, Inc. | ▲ | $627M |
| SLDB Solid Biosciences Inc. | ▲ | $593M |
| DBVT Dbv Technologies S.A. | ▶ | $536M |
| VALN Valneva Se | ▼ | $505M |
Where VIR sits on the market map
Life Sciences · Biological Products, (No Diagnostic Substances)
News
Vir Biotechnology, Inc. (VIR) stock news
Vir Biotechnology Sells 1.76 Million Shares to Gilead in $25M Stock Deal
Vir Bio and Gilead initiated a global collaboration to discover and engineer three innovative PRO-XTEN dual-masked T-cell ...
Can Gilead's deal with VIR boost its oncology pipeline and growth?
Gilead Sciences, Inc. GILD recently entered into a collaboration and license agreement with Vir Biotechnology, Inc. VIR to ...
FAQ
Vir Biotechnology, Inc. (VIR) stock forecast FAQ
What is the Vir Biotechnology, Inc. (VIR) stock forecast?
Our AI ranks Vir Biotechnology, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Vir Biotechnology, Inc. stock predictions?
For VIR, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 36.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 19.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Vir Biotechnology, Inc. forecasts updated?
Vir Biotechnology, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Vir Biotechnology, Inc.'s industry peers?
60 issuers in our coverage, VIR included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.